Accueil>>Signaling Pathways>> Others>>Ep23, 5'-DY647

Ep23, 5'-DY647

Catalog No.GC50337

High affinity fluorescently tagged aptamer for EpCam

Products are for research use only. Not for human use. We do not sell to patients.

Ep23, 5'-DY647 Chemical Structure

Taille Prix Stock Qté
50 ug
582,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

High affinity fluorescently tagged aptamer for EpCam (Kd = 39.42 nM in HT29 cells). Efficiently internalized upon binding to EpCAM. Exhibits rapid penetration of tumorspheres in vitro, as well as superior penetration, accumulation and retention in tumor xenografts in vivo than an antibody to the same target. For optimal binding aptamers require refolding into their tertiary structure prior to use. Please refer to the protocol for information regarding refolding and aptamer use in unfixed cell imaging and flow cytometry.

Shigdar et al (2011) RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 102 991 PMID:21281402 |Shigdar et al (2013) The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer. PLoS One. 8 e57613 PMID:23460885 |Xiang et al (2015) Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors. Theranostics. 5 1083 PMID:26199647

Avis

Review for Ep23, 5'-DY647

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ep23, 5'-DY647

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.